PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) today announced that President and CEO Hoji Alimi will hold a conference call on Monday, September 17, 2007 at 9:00 a.m. (EDT) to update investors on recent progress in the ongoing, open-label Phase II clinical trial of the company’s flagship product manufactured using Microcyn® Technology in patients with mildly infected diabetic foot ulcers. Oculus plans to highlight feedback from a meeting with prospective Phase III investigators scheduled to take place during the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. The purpose of the meeting is to review general clinical background on Microcyn including study design from the ongoing three-arm open Phase II study. During the call, Mr. Alimi will also comment on Phase II enrollment and plans for the clinical program going forward.
